![Matheus Dos Santos Dias, a researcher at the Netherlands Cancer Institute. He is working on a Lixte drug.](https://lixte.com/wp-content/uploads/2024/04/blog-featured-Matheus-Dos-Santos-Dias-150x150.jpg)
Article: LOS ANGELES BUSINESS JOURNAL: Lixte CEO Takes On a New Course
February 5, 2024![First in Human Episode #59 featuring Bas van der Baan](https://lixte.com/wp-content/uploads/2024/04/blog-podcast-first-in-human-episode-59-featuring-bas-van-der-baan-150x150.jpg)
Podcast: First in Human Episode #59 featuring Bas van der Baan
April 11, 2024LIXTE Biotechnology Holdings Provides Update on Progress with Proprietary LB-100 Compound to Enhance Chemotherapy and Immunotherapy Cancer Treatments. Three Clinical Trials Currently Underway for Treating Ovarian, Lung and Sarcoma Cancers.